Skyrizi®
Skyrizi® (risankizumab-rzaa) is an intravenous infusion given every 4 weeks x 3 doses indicated for the treatment of moderately to severely active Crohn’s disease.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
MANUFACTURER: AbbVie Inc. |
CLASS: Monoclonal Antibody |
WHAT IT TREATS: Crohn’s |
PRESCRIBED BY: Various |
HOW ADMINISTERED: Infusion |
FREQUENCY: Week 0, week 4, then every 12 weeks thereafter |
Length of infusion: 1 hour |
FOR MORE INFORMATION: |
